NIH's early-stage study, which enrolled 40 healthy adults, tested whether a monoclonal antibody called CIS43LS could safely provide a high level of protection from malaria following controlled ...

The phase 1 study tested both IV and SC dosing of CIS43LS, but only the IV form was taken forward into a challenge stage, in which patients were deliberately exposed to mosquitoes infected with ...

21 participants were given one dose of CIS43LS by either an intravenous infusion or an injection under the skin. The infusions ranged from 5 to 40 milligrams per kilogram (mg/kg) of body weight ...

The trial, sponsored by NIH's National Institute of Allergy and Infectious Diseases (NIAID), is the first to test mAb CIS43LS in humans. It aims to enroll up to 73 volunteers aged 18 through 50 ...

The trial, sponsored by NIH's National Institute of Allergy and Infectious Diseases (NIAID), is the first to test mAb CIS43LS in humans. It aims to enroll up to 73 volunteers aged 18 through 50 ...

The CIS43LS results – which have been published in the New England Journal of Medicine – were welcomed by Anthony Fauci, director the National Institute of Allergy and Infectious Diseases ...

An experimental monoclonal antibody developed at the U.S. National Institutes of Health (NIH) prevented malaria for up to nine months in volunteers exposed to the disease-causing parasite in a ...

NIH’s early-stage study, which enrolled 40 healthy adults, tested whether a monoclonal antibody called CIS43LS could safely provide a high level of protection from malaria following controlled ...